RCS - Hutchmed China Ltd - HUTCHMED Highlights Data at ESMO and ASH

HUTCHMED (China)Announcement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251127:nRSa1291Ja&default-theme=true

RNS Number : 1291J  Hutchmed (China) Limited  27 November 2025

Press Release

 

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

 

Hong Kong, Shanghai & Florham Park, NJ - Thursday, November 27, 2025:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from
several studies of compounds discovered by HUTCHMED will be presented at the
European Society for Medical Oncology ("ESMO") Asia Congress 2025, taking
place on December 5-7, 2025 in Singapore, and the American Society of
Hematology ("ASH") Annual Meeting taking place on December 6-9, 2025 in
Orlando, USA.

 

Results from a first-in-human study of the anti-CD47 monoclonal antibody
HMPL-A83 in advanced solid tumors, as well as from the phase II part of the
FRUSICA-2 registration study of the fruquintinib and sintilimab combination as
a second-line treatment for locally advanced or metastatic renal cell
carcinoma, will be presented at the ESMO Asia Congress 2025. Results from the
phase II part of the phase II/III study of surufatinib in combination with
camrelizumab and chemotherapy as a first-line treatment for metastatic
pancreatic cancer will also be reported. Details of the presentations are as
follows:

 

 Abstract title                                                                   Presenter/Lead author       Presentation details
 ESMO Asia Congress 2025 - SPONSORED STUDIES
 A first-in-human (FIH), dose escalation study of HMPL-A83 (A83), an anti-CD47    Ye Guo                      162MO | Mini Oral session: Developmental therapeutics and precision medicine
 monoclonal antibody (mAb) in patients (pts) with advanced solid tumors
(Shanghai, China)

                                                                                                            Sunday, December 7, 2025

                                                                                                              11:40 - 11:45 SGT

                                                                                                              Hall 407
 Fruquintinib monotherapy as second-line (2L) treatment in locally advanced or    Shanshan Wang               540O | Proffered Paper session: Genitourinary tumours
 metastatic renal cell carcinoma (RCC): results from phase 2 part of FRUSICA-2
(Shanghai, China)

                           Friday, December 5, 2025

                                                                                                              14:55 - 15:05 SGT

                                                                                                              Hall 402
 Surufatinib (S) in combination with camrelizumab (C), nab-paclitaxel and         Shukui Qin                  375P | Poster Display: Gastrointestinal tumours, non‑colorectal
 gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer:
(Nanjing, China)
 results from phase 2 part of a randomized, open-label, active-controlled,

 phase 2/3 study
 Osimertinib (osi) + savolitinib (savo) in EGFR-mutated (EGFRm) advanced          Se-Hoon Lee                 982P | Poster Display:
 non-small cell lung cancer (NSCLC) with MET overexpression and/or
(Seoul, Korea)
Thoracic tumours, metastatic
 amplification (OverExp/Amp) following progressive disease (PD) on osi:

 SAVANNAH Asian subset
 Patient-relevant Outcomes (PROs) from SACHI: a Phase 3 Trial of Savolitinib      Yongfeng Yu                 984P | Poster Display:
 (Savo) plus Osimertinib (Osi) versus Chemotherapy (Chemo) in EGFR-mutant
(Shanghai, China)
Thoracic tumours, metastatic
 (EGFRm) and MET-amplified (METamp) Advanced NSCLC after Progression on

 EGFR-TKIs
 Analysis of MET Amplification (METamp) with FISH and NGS Method in SACHI Trial   Longhua Sun                 988P | Poster Display:

(Nanchang, China)
Thoracic tumours, metastatic
 Progression pattern in patients (pts) with EGFR-mutant (EGFRm), MET-amplified    Haiyan Yang                 1002P | Poster Display:
 (METamp) advanced NSCLC treated with savolitinib (savo) plus osimertinib (osi)
(Changsha, China)
Thoracic tumours, metastatic

 MET testing and treatment (tx) sequencing after progression of disease (PD) on   Julia Rotow                 1005P | Poster Display:
 first-line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC
(Boston, US)
Thoracic tumours, metastatic
 and acquired MET overexpression and/or amplification (OverExp/Amp): Final

 analysis of a global real-world (rw) study
 ESMO Asia Congress 2025 - INVESTIGATOR-INITIATED STUDIES
 Fruquintinib Combined with TAS-102 with or without SBRT as Third- or             Chen Zhang/ Yi Wang         205P | Poster Display: Gastrointestinal tumours, colorectal
 Later-Line Treatment in Metastatic Colorectal Cancer: Preliminary Results from
(Ningbo, China)
 a Prospective Phase II Trial
 Efficacy and safety of fruquintinib combined with PD-1 inhibitor and chidamide   Guanghai Dai/ Miaomiao Gou  245eP | Poster Display: Gastrointestinal tumours, colorectal
 in MSS mCRC: a comparison with real-world bevacizumab plus anti-pd-1 and
(Beijing, China)
 chidamide arm

 The Efficacy and Safety of Fruquintinib (F) Plus FOLFIRI as Second-line  (2L)    Zhenyang Liu/ Xiaolin Yang  250eP | Poster Display: Gastrointestinal tumours, colorectal
 Treatment in Bevacizumab (Bev)-pretreated RAS-mutated (RAS‑m) Metastatic
(Changsha, China)
 Colorectal Cancer (mCRC)
 Real-world Observational Study of Fruquintinib in Combination with Irinotecan    Xiujuan Qu/ Lin Xu          255eP | Poster Display: Gastrointestinal tumours, colorectal
 and Capecitabine as Second-line Treatment in Patients with Advanced Colorectal
(Shenyang, China)
 Cancer
 Matching-Adjusted Indirect Comparison of Surufatinib versus High-Dose            Jianming Xu                 214P | Poster Display: Gastrointestinal tumours, colorectal
 Octreotide LAR in Advanced Extrapancreatic Neuroendocrine Tumors
(Beijing, China)
 Efficacy and safety of surufatinib in combination with CAPTEM as conversion      Xubao Liu/ Ziyao Wang       400P | Poster Display: Gastrointestinal tumours, non‑colorectal
 therapy in patients with unresectable pancreatic neuroendocrine tumors
(Chengdu, China)
 (pNETs): Data updates from a prospective, open-label study

 

Final analysis of long-term results of sovleplenib's ESLIM-01 China Phase III
study in in adult patients with chronic primary immune thrombocytopenia will
be presented at the 2025 ASH Annual Meeting. Details of the presentation is as
follows:

 

 Abstract title                                                              Presenter/Lead author  Presentation details
 2025 ASH Annual Meeting - SPONSORED STUDIES
 Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term  Renchi Yang            843 | Oral Abstract Session
 treatment with sovleplenib in adults with chronic primary immune
(Tianjin, China)

 thrombocytopenia                                                                                   Monday, December 8, 2025

                                                                                                    15:15 - 15:30 EST

                                                                                                    Room OCCC - W304EFGH

 

About Fruquintinib

Fruquintinib is a selective oral inhibitor of all three vascular endothelial
growth factor receptors ("VEGFR") -1, ‑2 and -3. Fruquintinib is
co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and
Company under the brand name ELUNATE(®). Takeda holds the exclusive worldwide
license to further develop, commercialize, and manufacture fruquintinib
outside mainland China, Hong Kong and Macau, marketing it under the brand name
FRUZAQLA(®).

 

About HMPL-A83

HMPL-A83 is an investigational IgG4-type humanized anti-CD47 monoclonal
antibody that exhibits high affinity for CD47. HMPL-A83 blocks CD47 binding to
Signal regulatory protein (SIRP) α and disrupts the "do not eat me" signal
that cancer cells use to shield themselves from the immune system. HUTCHMED
currently retains all rights to HMPL-A83 worldwide.

 

About Savolitinib

Savolitinib is an oral, potent and highly selective MET tyrosine kinase
inhibitor that has demonstrated clinical activity in advanced solid tumors. It
blocks atypical activation of the MET receptor tyrosine kinase pathway that
occurs because of mutations (such as exon 14 skipping alterations or other
point mutations), gene amplification or protein overexpression.
Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and
commercialized by AstraZeneca under the brand name ORPATHYS(®).

 

About Surufatinib

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively
inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast
growth factor receptor (FGFR), which both inhibit angiogenesis, and colony
stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated
macrophages, promoting the body's immune response against tumor cells.
Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA(®).
HUTCHMED currently retains all rights to surufatinib worldwide.

 

About Sovleplenib

Sovleplenib is a novel, investigational, selective small molecule inhibitor
for oral administration targeting the spleen tyrosine kinase, also known as
Syk. Syk is a major component in B-cell receptor and Fc receptor signaling and
is an established target for the treatment of multiple subtypes of B-cell
lymphomas and autoimmune disorders. HUTCHMED currently retains all rights to
sovleplenib worldwide.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, the first of
which is also approved around the world including in the US, Europe and Japan.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the US Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events, including but not limited to its
expectations regarding the therapeutic potential of fruquintinib, HMPL-A83,
surufatinib, savolitinib and sovleplenib, the further clinical development for
fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib, its
expectations as to whether any studies on fruquintinib, HMPL-A83, surufatinib,
savolitinib and sovleplenib would meet their primary or secondary endpoints,
and its expectations as to the timing of the completion and the release of
results from such studies. Such risks and uncertainties include, among other
things, assumptions regarding enrollment rates and the timing and availability
of subjects meeting a study's inclusion and exclusion criteria; changes to
clinical protocols or regulatory requirements; unexpected adverse events or
safety issues; the ability of fruquintinib, HMPL-A83, surufatinib, savolitinib
and sovleplenib, including as combination therapies, to meet the primary or
secondary endpoint of a study, to obtain regulatory approval in different
jurisdictions and to gain commercial acceptance after obtaining regulatory
approval; the potential markets of fruquintinib, HMPL-A83, surufatinib,
savolitinib and sovleplenib for a targeted indication, and the sufficiency of
funding. In addition, as certain studies rely on the use of other drug
products such as camrelizumab and osimertinib as combination therapeutics,
such risks and uncertainties include assumptions regarding their safety,
efficacy, supply and continued regulatory approval. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. For further discussion of
these and other risks, see HUTCHMED's filings with the US Securities and
Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM.
HUTCHMED undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new information,
future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be
available in all countries, or may be available under different trademarks,
for different indications, in different dosages, or in different strengths.
Nothing contained herein should be considered a solicitation, promotion or
advertisement for any prescription drugs including the ones under development.

 

CONTACTS
 Investor Enquiries                                  +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                    +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                     (mailto:HUTCHMED@fticonsulting.com)
    Ben Atwell / Tim Stamper                            +44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)
 Brunswick - Zhou Yi                                 +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                     (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                     Nominated Advisor and Joint Broker
 Atholl Tweedie / Emma Earl / Rupert Dearden         +44 20 7886 2500

 Cavendish                                           Joint Broker
 Geoff Nash / Nigel Birks                            +44 20 7220 0500

 Deutsche Numis                                      Joint Broker
 Freddie Barnfield / Jeffrey Wong / Duncan Monteith  +44 20 7260 1000

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPGCGGUPAGPQ



            Copyright 2019 Regulatory News Service, all rights reserved